Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Shares Outstanding data on record, last reported at $52.4 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 20.73% year-over-year to $52.4 million; the TTM value through Sep 2025 reached $52.4 million, up 20.73%, while the annual FY2024 figure was $45.6 million, 72.09% up from the prior year.
  • Shares Outstanding reached $52.4 million in Q3 2025 per ABEO's latest filing, up from $51.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $99.0 million in Q1 2021 and bottomed at $4.1 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $29.0 million, with a median of $24.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: tumbled 95.26% in 2021, then soared 265.87% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $5.9 million in 2021, then soared by 200.94% to $17.7 million in 2022, then soared by 49.69% to $26.5 million in 2023, then surged by 72.09% to $45.6 million in 2024, then increased by 14.8% to $52.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $52.4 million in Q3 2025, $51.2 million in Q2 2025, and $49.0 million in Q1 2025.